Evaluation of the pattern and prognostic implications of anti-p53 in hepatocellular carcinoma

Singapore Medical Journal

Volumn 48, Issue 1, 2007, Pages 41-44

  Akere, A ^a   Otegbayo, Jesse Abiodun ^a  

^a UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

Anti p53; Hepatocellular carcinoma; Serum anti p53

Indexed keywords

AUTOANTIBODY; PROTEIN P53; CANCER ANTIBODY;

ADULT; ANTIBODY DETECTION; ARTICLE; CANCER PATIENT; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; NIGERIA; PREVALENCE; PROGNOSIS; PROTEIN BLOOD LEVEL; CASE CONTROL STUDY; IMMUNOLOGY; LIVER TUMOR; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; ANTIBODIES, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIGERIA; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33846995098     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Di Cesare E, Previti M, Lombardo F, et al. Serum anti-p53 antibodies in patients with type 1 diabetes. Ann Clin Lab Sci 2001; 31:253-8.
2. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993; 329:1318-27.
3. Comment in: N Engl J Med 1994; 330:864-5..
4. Saffroy R, Lelong JC, Azoulay D, et al. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. Br J Cancer 1999; 79:604-10.
5. Ding SF, Habib NA. Loss of heterozygosity in liver tumours. J Hepatol 1995; 22:230-8.
6. Ndububa DA, Yakicier CM, Ojo OS, et al. p53 codon 249 mutation in hepatocellular carcinomas from Nigeria. Afr J Med Sci 2001; 30:125-7.
7. Soussi T. The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. Immunol Today 1996; 17:354-6.
8. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002; 8:385-92.
9. Shiota G, Kishimoto Y, Suyama A, et al. Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma. J Hepatol 1997; 27:661-8.
10. Reid AE, Liang TJ. The search for the ultimate screening test for hepatocellular carcinoma continues. Hepatology 1994; 19:255-7.
11. Soini Y, Chia SC, Bennett WP, et al. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinoma from Mexico. Carcinogenesis 1996; 17:1007-12.
12. Sitruk V, Vaysse J, Chevret S, et al. [Prevalence and prognostic value of serum anti-p53 in hepatocellular carcinoma. A study of 159 patients]. Gastroenterol Clin Biol 2000; 24:1159-63. French.
13. Tangkijvanich P, Janchai A, Charuruks N, et al. Clinical associations and prognostic significance of serum anti-p53 antibodies in Thai patients with hepatocellular carcinoma. Asian Pac J Allergy Immunol 2000; 18:237-43.
14. De Benedetti VM, Welsh JA, Trivers GE, et al. p53 is not mutated in hepatocellular carcinomas from Alaska natives. Cancer Epidemiol Biomarkers Prev 1995; 4:79-82.
15. Ryder SD, Rizzi PM, Volkmann M, et al. Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma. J Clin Pathol 1996; 49:295-9.
16. Charuruks N, Tangkijvanich P, Voravud N, et al. Clinical significance of p53 antigen and anti-p53 antibodies in the sera of hepatocellular carcinoma patients. J Gastroenterol 2001; 36:830-6.
17. Comment in: J Gastroenterol 2001; 36:865-6.
18. Raedle J, Oremek G, Truschnowitsch M, et al. Clinical evaluation of autoantibodies to p53 protein in patients with chronic liver disease and hepatocellular carcinoma. Eur J Cancer 1998; 34:1198-203.
19. Shiota G, Kishimoto Y, Suyama A, et al. Prognostic significance of serum anti-p53 in patients with hepatocellular carcinoma. J Hepatol 1997; 27:661-8.